Ultrasound parameters in osteoporotic patients treated with salmon calcitonin: A longitudinal study
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Speed of sound (SOS) and broadband ultrasound attenuation (BUA) of ultrasound (US) in bone have been proposed as alternatives to radiation-based methods for the quantitative assessment of osteoporosis. However, the usefulness of US in monitoring response to treatment in osteoporotic patients has yet to be defined. To compare US with bone mineral density (BMD), we studied 112 osteoporotic women (age range 50–64 years). Seventy-eight of them were treated with salmon calcitonin nasal spray (CT; 200 IU/day, 1 month on and 1 month off) and calcium (500 mg/day); 34 patients were given only calcium. One hundred and four women complied with treatment throughout the 2-year study period. At baseline and after 1 and 2 years we measured BMD at lumbar spine by dual-energy X-ray absorptiometry (DXA), and SOS, BUA and Stiffness index, by an Achilles ultrasound unit. Moreover, biochemical markers of bone turnover (alkaline phosphatase, osteocalcin and hydroxyproline) were also measured at baseline and after 6, 12 and 24 months. In the calcitonin-treated group at the end of the study period BMD had increased by 1.99%, SOS by 0.20%, BUA by 0.88% and Stiffness by 2.12%. By contrast in the calcium-treated group all parameters had decreased (BMD, −2.66%; SOS, −0.55%; BUA, −3.30%; Stiffness, −6.0%) by the end of the study period. The differences between groups were significant for BMD, SOS and Stiffness. At baseline a significant, but weak correlation was found between BMD and US parameters. The correlation coefficients between percentage changes at the end of the study period, in BMD and in SOS, BUA and Stiffness, were all significant (p<0.001), being 0.41, 0.53 and 0.57 respectively. In conclusion, ultrasound measurements carried out in conjunction with BMD measurements will yield a more comprehensive assessment of skeletal status and may be helpful in monitoring the response to treatment in osteoporotic patients.
- Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt T. Bone density at various sites for prediction of hip fractures. The study of Osteoporotic Fractures Research Group. Lancet 1993;341:72–5.
- Riggs BL, Melton LJ III. Involutional osteoporosis. N Engl J Med 1986;314:1676–86.
- Parfitt AM. Implications of architecture for the pathogenesis and prevention of vertebral fracture. Bone 1992;13:41–7.
- Cooper C, Aihie A. Osteoporosis: recent advances in pathogenesis and treatment. Q J Med 1994;87:203–9.
- Genant HK, Gluer CC, Lotz JC. Gender differences in bone density, skeletal geometry and fracture biomechanics. Radiology 1994;190:636–40.
- Gluer CC, Wu CY, Jergas M, Goldstein SA, Genant HK. Three quantitative ultrasound parameters reflect bone structure. Calcif Tissue Int 1994;55:46–52.
- Camporeale A, Cepollaro C, Zacchei F, Montagnani M, Agnusdei D, Gennari C. Ultrasound transmission velocity in normal and osteoporotic postmenopausal women. In: Christiansen C, Overgaard K, editors. Osteoporosis 90. Copenhagen: Osteopress ApS, 1990:670–2.
- Herd RJM, Ramalingham T, Ryan PJ, Fogelman I, Blake GM. Measurements of broadband ultransonic attenuation in the calcaneus in premenopausal and postmenopausal women. Osteoporosis Int 1992;2:247–51.
- Yamada M, Ito M, Hayashi K, Nakamura T. Calcaneus as a site for assessment of bone mineral density: evaluation in cadavers and healthy volunteers. AJR 1993;161:621–7.
- Agren M, Karellas A, Leahey D, Marks S, Baran D. Ultrasound attenuation at the calcaneus: a sensitive and specific discriminator of osteopenia in postmenopausal women. Calcif Tissue Int 1991;48:240–4.
- Young H, Howey S, Purdie DW. Broadband ultrasound attenuation compared with dual-energy X-ray absorptiometry in screening for postmenopausal low bone density. Osteoporosis Int 1993;3:160–4.
- Faulkner KG, McClung MR, Coleman LJ, Kingston-Sandahl E. Quantitative ultrasound of the heel: correlation with densitometric measurements at different skeletal sites. Osteoporosis Int 1994;4:42–7.
- Stewart A, Reid DM, Porter RW. Broadband ultrasound attenuation and dual energy X-ray absorptiometry in patients with hip fractures: which technique discriminates fracture risk? Calcif Tissue Int 1994;54:466–9.
- Bauer DC, Gluer CC, Genant HK, Stone K, for the fracture Intervention Trial Research Group. Quantitative ultrasound and vertebral fracture in postmenopausal women. J Bone Miner Res 1995;10:353–8.
- Schott AM, Weill-Engerer S, Hans D, Duboeuf F, Delmas PD, Meunier PJ. Ultrasound discriminates patients with hip fracture equally well as dual energy X-ray absorptiometry and independently of bone mineral density. J. Bone Miner Res 1995;10:243–9.
- Heaney RP, Avioli LV, Chesnut CH III, Lappe J, Recker RR, Brandenburger GH. Ultrasound velocity through bone predicts incident vertebral deformity. J Bone Miner Res 1995;10:341–5.
- Hans D, Dargent P, Schott AM, Sebert JL, Cormier C, Kotski PO, Delmas PD, Pouilles JM, Breart G, Meunier PJ. Ultrasound parameters predict hip fracture independently of hip bone density: the EPIDOS prospective study. J Bone Miner Res 1995;10 (Suppl 1):S169.
- Bauer DC, Gluer CC, Pressman AR, Vogt TM, Ensrud KE, Cauley JA, Fox KM, Black DM, Genant HK, Cummings SR, for the Study of Osteoporotic Fractures Research Group. Broadband ultrasonic attenuation (BUA) and the risk of fracture: a prospective study. J Bone Miner Res 1995;10 (Suppl 1):S175.
- Reginster JY, Meurmans L, Deroisy R, Jupsin I, Biquet I, Albert A, Franchimont P. A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium. Eur J Clin Invest 1994;24:565–9.
- Overgaard K. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study. Calcif Tissue Int 1994;55:82–6.
- Lyritis GP, Magiasis B, Tsakalakos N. Prevention of bone loss in early nonsurgical and nonosteoporotic high turnover patients with salmon calcitonin: the role of biochemical bone markers in monitoring high turnover patients under calcitonin treatment. Calcif Tissue Int 1995;56:38–41.
- Mazzuoli GF, Passeri M, Gennari C, Minisola S, Antonelli R, Valtorta C, Palummeri E, Cervellin GF, Gonnelli S, Francini G. Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 1986;38:3–8.
- Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C. Bone turnover in postmenopausal osteoporosis: effect of calcitonin treatment. J Clin Invest 1988;82:1268–74.
- Gennari C, Agnusdei D, Montagnani M, Gonnelli S, Civitelli R. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss. Calcif Tissue Int 1992;50:381–3.
- Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992;305:556–61.
- Gennari C, Agnusdei D, Camporeale A. Effect of salmon calcitonin nasal spray on bone mass in patients with high turnover osteoporosis. Osteoporosis Int 1993;Suppl 1:S208–10.
- Rico H, Revilla M, Hernandez ER, Villa LF, Alvarez de Buergo M. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. Calcif Tissue Int 1995;56:181–5.
- Cepollaro C, Zacchei F, Borracelli D, Palmieri R, Gonnelli S, Agnusdei D, Gennari C. Precision of new ultsrasound bone densitometers: correlation with absorptiometry methods. In: Proceedings of ultrasonic assessment of bone II, Bath, 23 June 1992:19.
- Zerbe GO. Randomization analysis of the completely randomized design extended to growth and response curves. J Am Stat Assoc 1979;74:215–21.
- Rico H, Hernandez ER, Revilla M, Gomez-Castresana F. Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. Bone Miner 1992;16:131–8.
- Kanis JA, Johnell O, Gullberg B, Allander E, Dilsen G, Gennari C, Lopes Vaz A, Lyritis GP, Mazzuoli G, Miravet L, Passeri M, Perez Cano R, Rapado A, Ribot C. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ 1992;305:1124–8.
- Heaney RP, Avioli LV, Chesnut CH III, Lappe J, Recker RR, Brandenburger GH. Osteoporotic bone fragility: detection by ultrasound transmission velocity. JAMA 1989;261:2986–90.
- Hans D, Arlot ME, Schott AM, Roux JP, Kotzki PO, Meunier PJ. Do ultrasound measurements on the os calcis reflect more the bone microarchitecture than the bone mass? A two dimensional histomorphometric study. Bone 1995;16:295–300.
- Palacios S, Menendez C, Calderon J, Rubio S. Spine and femur density and broadband ultrasound attenuation of the calcaneus in normal Spanish women. Calcif Tissue Int 1993;52:99–102.
- Schott AM, Hans D, Sornay-Rendu E, Delmas PD, Meunier PJ. Ultrasound measurement on os calcis: precision and age-related changes in a normal female population. Osteoporosis Int 1993;3:249–54.
- Cepollaro C, Agnusdei D, Gonnelli S, Martini G, Borracelli D, Palmieri R, Parisi G, Gennari C. Ultrasonographic assessment of bone in normal Italian males and females. Br J Radiol 1995;68:910–4.
- Schott AM, Hans D, Delmas PD, Meunier PJ. Changes with age in ultrasound measurement: a two year prospective study in 113 healthy postmenopausal women. Osteoporosis Int 1995;5:307.
- Naessen T, Mallmin H, Ljunghall S. Heel ultrasound in women after long-term ERT compared with bone densities in the forearm, spine and hip. Osteoporosis Int 1995;5:205–10.
- Ultrasound parameters in osteoporotic patients treated with salmon calcitonin: A longitudinal study
Volume 6, Issue 4 , pp 303-307
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Bone mineral density
- Salmon calcitonin
- Industry Sectors